マーケットレポート詳細
抗体医薬品：技術および世界市場2026年予測
Antibody Drugs: Technologies and Global Markets
- 出版元：BCC Research 出版元について
- 発行年：2021年11月
- 定価 Single User License(1名様ライセンス)US$5,500 (米国ドル) /2 to 5 Users License(5名様)$6,600 /Site License $7,920 / Enterprise License $9,504
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文133ページになります。
- 商品コード：BCC326
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
抗体医薬品の世界市場規模は2021年段階で1,267億ドルと推計されます。同市場規模はこの先2026年には2,086億ドルへ達すると予測されます。当レポートでは、抗体医薬品の市場/技術的背景、市場ダイナミクス、各種セグメント別市場分析(技術タイプ別、用途別)、規制側面、特許レビュー/新展開、競合状況、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。
【レポート構成概要】
◆イントロダクション
・調査目的
・調査対象
・調査手法
◆サマリーと調査ハイライト
◆市場/技術的背景
・抗体と抗原
・抗体機能
・モノクローナル抗体
◆市場ダイナミクス
・技術的問題とHAMA問題
・市場ドライバー
・市場課題
・COVID-19による抗体医薬品市場への影響
◆抗体医薬品市場、技術タイプ別
タイプ別
地域別
・ヒト化モノクローナル抗体
・キメラモノクローナル抗体
・ヒトモノクローナル抗体
・マウスモノクローナル抗体
（※地域別のデータ掲載）
製造プロセス別
・ヒト化モノクローナル抗体
・キメラモノクローナル抗体
・ヒトモノクローナル抗体
・マウスモノクローナル抗体
（※製造プロセス別のデータ掲載）
※市場予測データ-2026年掲載
◆抗体医薬品市場、用途別
疾患別
・自己免疫疾患
・固形腫瘍
・リンパ腫/白血病/多発性骨髄腫
・その他
※市場予測データ-2026年掲載
※抗体タイプ別、地域別のデータ掲載
◆規制側面
・モノクローナル抗体の新規承認
・リコールと安全警告
◆特許レビュー/新展開
・新展開
・臨床試験段階
◆競合状況
・合併と買収
・抗体医薬品
◆主要企業プロフィール
・ABBVIE INC.
・AMGEN INC.
・ALEXION PHARMACEUTICALS
・ASTRAZENECA PHARMACEUTICALS
・BIOGEN
・BRISTOL-MYERS SQUIBB CO
・ELI LILLY
・F. HOFFMANN-LA ROCHE AG
・FRESENIUS KABI
・GLAXOSMITHKLINE
・GENMAB A/S
・GILEAD SCIENCES INC.
・JOHNSON & JOHNSON
・MERCK & CO. INC.
・MERCK KGAA
・NOVARTIS AG
・PFIZER INC.
・REGENERON PHARMACEUTICALS
・SANOFI S.A.
・SEAGEN
・武田薬品工業株式会社
・UCB CO.
(全133頁)
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
What's New in This Update?
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Antibodies and Antigens
Antibody Functions
Monoclonal Antibodies
- History of Monoclonal Antibodies
- Monoclonal Antibodies: Advantages and Disadvantages
- Types of Monoclonal Antibodies
- Manufacturing Technologies of Monoclonal Antibodies
- Applications of Monoclonal Antibodies
Chapter 4 Market Dynamics
Technical Issues and HAMA Problem
- Human Anti-mouse Antibody (HAMA)
- Factors Affecting mAb Drugs
Market Drivers
- Increasing Prevalence of Chronic Diseases
- Aging Population
- Advancements in Manufacturing Technologies
- New Product Launches
- Licensing and Collaboration Agreements
Market Challenges
- Price Controls
- Regulatory Approval Pressures
- Entry of Biosimilars
Impact of COVID-19 on Antibody Drugs Market
Chapter 5 Market Breakdown by Technology Type
Market by Type
- Market Overview
- Market Revenue
- Market Share
Market by Region
- Market Overview
- Market Revenue
- Market Share
- Humanized Monoclonal Antibodies
- Chimeric Monoclonal Antibodies
- Human Monoclonal Antibodies
- Murine Monoclonal Antibodies
Market by Manufacturing Process
- Market Overview
- Market Revenue
- Market Share
- Market Analysis of Humanized Monoclonal Antibodies by Manufacturing Process
- Market Analysis of Chimeric Monoclonal Antibodies by Manufacturing Process
- Market Analysis of Human Monoclonal Antibodies by Manufacturing Process
- Market of Murine Monoclonal Antibodies by Manufacturing Process
Chapter 6 Market Breakdown by Application
Market by Diseases
- Market Overview
- Market Revenue
- Market Share
- Autoimmune Disease
- Solid Tumors
- Lymphoma, Leukemia and Multiple Myeloma
- Others
Chapter 7 Regulatory Aspects
New Approvals of Monoclonal Antibodies
Recalls and Safety Alerts
Chapter 8 Patent Review/ New Developments
New Developments
Clinical Trial Phases
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV Clinical Trials
Chapter 9 Competitive Landscape
Mergers and Acquisitions
Antibody Drugs
- Market Shares of Humanized Monoclonal Antibodies
- Market Shares of Human Monoclonal Antibodies
- Market Shares of Chimeric Monoclonal Antibodies
- Market Shares of Murine Monoclonal Antibodies
Chapter 10 Company Profiles
ABBVIE INC.
AMGEN INC.
ALEXION PHARMACEUTICALS
ASTRAZENECA PHARMACEUTICALS
BIOGEN
BRISTOL-MYERS SQUIBB CO
ELI LILLY
F. HOFFMANN-LA ROCHE AG
FRESENIUS KABI
GLAXOSMITHKLINE
GENMAB A/S
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
MERCK & CO. INC.
MERCK KGAA
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS
SANOFI S.A.
SEAGEN
TAKEDA PHARMACEUTICAL CO., LTD.
UCB CO.
List of Tables
Summary Table : Global Market for Antibody Drugs, by Antibody Type, Through 2026
Table 1 : Evolution of Monoclonal Antibodies
Table 2 : Advantages and Disadvantages of Monoclonal Antibodies
Table 3 : Murine Monoclonal Antibodies
Table 4 : Chimeric Monoclonal Antibodies
Table 5 : Humanized Monoclonal Antibodies
Table 6 : Human Monoclonal Antibodies
Table 7 : Differences between Hybridoma and Recombinant Technologies
Table 8 : Murine Monoclonal Antibodies and Their Applications
Table 9 : Chimeric Monoclonal Antibodies and Their Applications
Table 10 : Human Monoclonal Antibodies and Their Applications
Table 11 : Humanized Monoclonal Antibodies and Their Applications
Table 12 : Global Market for Antibody Drugs, by Antibody Type, Through 2026
Table 13 : Global Market for Antibody Drugs, by Region, Through 2026
Table 14 : Global Market for Humanized Monoclonal Antibodies, by Region, Through 2026
Table 15 : Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2026
Table 16 : Global Market for Human Monoclonal Antibodies, by Region, Through 2026
Table 17 : Global Market for Murine Monoclonal Antibodies, by Region, Through 2026
Table 18 : Global Market for Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 19 : Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 20 : Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 21 : Global Market for Human Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 22 : Global Market for Murine Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 23 : Global Market for Antibody Drugs, by Disease, Through 2026
Table 24 : Types of Autoimmune Diseases
Table 25 : Global Market for Antibody Drugs in Autoimmune Disease, by Antibody Type, Through 2026
Table 26 : Global Market for Antibody Drugs in Autoimmune Disease, by Region, Through 2026
Table 27 : Types of Cancer by the Tissue of Origin
Table 28 : Global Market for Antibody Drugs in Solid Tumor, by Antibody Type, Through 2026
Table 29 : Global Market for Antibody Drugs in Solid Tumor, by Region, Through 2026
Table 30 : Types of Leukemia
Table 31 : Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Antibody Type, Through 2026
Table 32 : Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Region, Through 2026
Table 33 : Global Market for Antibody Drugs in Other Diseases, by Antibody Type, Through 2026
Table 34 : Global Market for Antibody Drugs in Other Diseases, by Region, Through 2026
Table 35 : Newly Approved Monoclonal Antibodies, 2019-August 2021
Table 36 : Recalls and Safety Alerts, 2019-August 2021
Table 37 : Monoclonal Antibodies in Phase I Clinical Trials
Table 38 : Monoclonal Antibodies in Phase II Clinical Trials
Table 39 : Monoclonal Antibodies in Phase III Clinical Trials
Table 40 : Monoclonal Antibodies in Phase IV Clinical Trials
Table 41 : M&A: Pharmaceutical Companies
Table 42 : AbbVie Inc.: Business Segment
Table 43 : AbbVie Inc.: Financial Performance, Through 2020
Table 44 : Amgen: Financial Performance, Through 2020
Table 45 : AstraZeneca: Financial Performance, 2018-2020
Table 46 : Bristol-Myers Squibb: Financial Performance, 2018-2020
Table 47 : Eli Lilly: Business Segment
Table 48 : Eli Lilly: Financial Performance, 2018-2020
Table 49 : F. Hoffmann-La Roche: Business Segment
Table 50 : F. Hoffmann-La Roche: Financial Performance, 2018-2020
Table 51 : GlaxoSmithKline: Product Segment
Table 52 : Johnson & Johnson: Business Segment
Table 53 : Johnson & Johnson: Financial Performance, 2018-2020
Table 54 : Merck & Co. Inc.: Business Segment
Table 55 : Merck & Co. Inc.: Financial Performance, 2018-2020
Table 56 : Pfizer: Business Segment
Table 57 : Sanofi: Business Segment
Table 58 : Sanofi: Financial Performance, 2018-2020
List of Figures
Summary Figure : Global Market for Antibody Drugs, by Antibody Type, 2019-2026
Figure 1 : Global Market for Antibody Drugs, by Antibody Type, 2019-2026
Figure 2 : Global Market Shares of Antibody Drugs, by Antibody Type, 2020
Figure 3 : Global Market for Antibody Drugs, by Region, 2019-2026
Figure 4 : Global Market Shares of Antibody Drugs, by Region, 2020
Figure 5 : Global Market for Humanized Monoclonal Antibodies, by Region, 2019-2026
Figure 6 : Global Market for Chimeric Monoclonal Antibodies, by Region, 2019-2026
Figure 7 : Global Market for Human Monoclonal Antibodies, by Region, 2019-2026
Figure 8 : Global Market for Murine Monoclonal Antibodies, by Region, 2019-2026
Figure 9 : Global Market for Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 10 : Global Market Shares of Antibody Drugs, by Manufacturing Process, 2020
Figure 11 : Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 12 : Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 13 : Global Market for Human Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 14 : Global Market for Murine Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 15 : Global Market for Antibody Drugs, by Disease, 2019-2026
Figure 16 : Global Market Shares of Antibody Drugs, by Disease, 2020
Figure 17 : Global Market for Antibody Drugs in Autoimmune Disease, by Antibody Type, 2019-2026
Figure 18 : Global Market for Antibody Drugs in Autoimmune Disease, by Region, 2019-2026
Figure 19 : Global Market for Antibody Drugs in Solid Tumor, by Antibody Type, 2019-2026
Figure 20 : Global Market for Antibody Drugs in Solid Tumor, by Region, 2019-2026
Figure 21 : Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Antibody Type, 2020-2026
Figure 22 : Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Region, 2020-2026
Figure 23 : Global Market for Antibody Drugs in Other Diseases, by Antibody Type, 2020-2026
Figure 24 : Global Market for Antibody Drugs in Other Diseases, by Region, 2020-2026
Figure 25 : Global Market Shares of Humanized Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 26 : Global Market Shares of Human Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 27 : Global Market Shares of Chimeric Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 28 : Global Market Shares of Murine Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 29 : AbbVie Inc.: Net Revenue Share, by Business Segment, 2020
Figure 30 : AbbVie Inc.: Net Revenue Share, by Region, 2020
Figure 31 : Amgen: Sales Share, by Product, 2020
Figure 32 : Amgen: Revenue Share, by Region, 2020
Figure 33 : AstraZeneca: Sales Share, by Segment, 2020
Figure 34 : AstraZeneca: Revenue Share, by Region, 2020
Figure 35 : Bristol Myers Squibb: Sales Share, by Product, 2020
Figure 36 : Bristol-Myers Squibb: Total Revenue Share, by Region, 2020
Figure 37 : Eli Lilly: Total Sales Share, by Product Segment, 2020
Figure 38 : Eli Lilly: Total Revenue Share, by Region, 2020
Figure 39 : F. Hoffmann-La Roche: Total Sales Share, by Product Segment, 2020
Figure 40 : F. Hoffmann-La Roche: Total Revenue Share, by Region, 2020
Figure 41 : Johnson & Johnson: Total Sales Share, by Business Segment, 2020
Figure 42 : Johnson & Johnson: Total Revenue Share, by Region, 2020
Figure 43 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2020
Figure 44 : Merck & Co. Inc.: Revenue Share, by Region, 2020
Figure 45 : Sanofi: Net Sales Share, by Business Segment, 2020
Figure 46 : Sanofi: Net Sales Share, by Region, 2020